Vertex Pharmaceuticals Inc

Most Recent

  • uploads///tesla renaissance technologies
    Consumer

    How Did Tesla Become Renaissance Technologies’ Gem?

    In the fourth quarter of 2019, Tesla was Renaissance Technologies’ second-largest holding. Renaissance is one of the largest hedge funds in the US.

    By Rabindra Samanta
  • uploads///AdobeStock_
    Consumer

    Renaissance Technologies: Top Investments

    Renaissance Technologies had a strong investment in the healthcare sector in Q2 2019. The healthcare sector makes up 18.16% of the firm’s total portfolio.

    By Rabindra Samanta
  • uploads///AdobeStock_
    Earnings Report

    Amarin’s Q2 Earnings and Robust 2019 Outlook

    Amarin Corporation (AMRN) reported its Q2 2019 earnings yesterday. Here’s how the stock, investors, and peer pharma stocks reacted.

    By Sushree Mohanty
  • uploads///AdobeStock_
    Earnings Report

    Vertex Pharmaceuticals Raises Guidance, Shares Follow

    Yesterday, Vertex Pharmaceuticals reported its second-quarter results after the market closed. Today, it was up 1.73% in the premarket session.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Analysts Have Raised Their Target Price for VRTX in March

    Wall Street analysts expect a potential upside of 14.17% for Vertex Pharmaceuticals (VRTX) based on the stock’s closing price on March 21.

    By Margaret Patrick
  • uploads///microbiology _
    Company & Industry Overviews

    Why CRISPR Therapeutics Stock Rose ~13.05% Yesterday

    On January 7, CRISPR Therapeutics stock rose ~13.05% to $34.22 from its previous close of $30.27 on January 4.

    By Daniel Collins
  • uploads///SRPT EPS
    Company & Industry Overviews

    A Look at Sarepta Therapeutics’ Recent Developments

    In the first nine months of 2018, Sarepta Therapeutics’ (SRPT) net income and EPS amounted to -$221.0 million and -$3.38, respectively, compared to -$26.7 million and -$0.47 in the same period the prior year.

    By Daniel Collins
  • uploads///SRPT
    Company & Industry Overviews

    How Is Sarepta Therapeutics Positioned in January?

    In the first nine months of 2018, Sarepta Therapeutics’ net revenues grew ~123% YoY to reach $216.6 million from $97.3 million.

    By Daniel Collins
  • uploads///SRPT
    Company & Industry Overviews

    Understanding Sarepta Therapeutics’ Operational Performance

    Sarepta Therapeutics’ (SRPT) R&D (research and development) expenses rose YoY (year-over-year) to $86.58 million.

    By Kenneth Smith
  • uploads///VRTX
    Company & Industry Overviews

    Vertex Pharmaceuticals’ Gross Margin Trends

    Kalydeco, Orkambi, and Symdeko are Vertex Pharmaceuticals’ (VRTX) products on the market.

    By Kenneth Smith
  • uploads///VRTX
    Company & Industry Overviews

    Do Analysts See Any Upside for Vertex Stock?

    Of the 25 analysts covering Vertex Pharmaceuticals (VRTX), 21 recommend “buy” or a higher rating, and four recommend “hold.”

    By Kenneth Smith
  • uploads///syringe _
    Company & Industry Overviews

    Taking Stock of Vertex’s Performance

    Vertex Pharmaceuticals (VRTX) focuses on developing cystic fibrosis therapies and bringing them to market.

    By Kenneth Smith
  • uploads///BLUE
    Company & Industry Overviews

    Do Analysts See Any Upside for bluebird bio Stock?

    In this year’s third quarter, bluebird bio (BLUE) generated net interest income of $4.59 million.

    By Kenneth Smith
  • uploads///BLUE
    Company & Industry Overviews

    Understanding bluebird bio’s Operational Performance

    In 2018 and 2019, bluebird bio (BLUE) is expected to generate revenues of $43.62 million and $67.0 million, respectively.

    By Kenneth Smith
  • uploads///dna _
    Company & Industry Overviews

    Taking Stock of bluebird bio’s Performance

    In the third quarter, bluebird bio’s total revenue rose YoY (year-over-year) to $11.53 million from $7.71 million.

    By Kenneth Smith
  • uploads///Biomarin
    Company & Industry Overviews

    How BioMarin Pharmaceutical’s Financials Look in November

    BioMarin Pharmaceutical’s (BMRN) net revenues over the first nine months of this year amounted to $1.1 billion compared to $955.3 million in the same period the prior year.

    By Daniel Collins
  • uploads///dna _
    Earnings Report

    Biogen Surpassed Estimates in Q3 2018, Reports Strong Growth

    Today, Biogen (BIIB) reported EPS of $7.40 on revenues of ~$3.44 billion. BIIB beat the EPS estimate of $6.78 on revenues of ~$3.33 billion.

    By Mike Benson
  • uploads///blood _
    Company & Industry Overviews

    How Is Vertex Pharmaceuticals Positioned in October?

    Vertex announced on October 10 that the FDA has lifted the clinical hold and accepted its Investigational New Drug Application for CTX001.

    By Kenneth Smith
  • uploads///NBIX
    Company & Industry Overviews

    Analysts Are Mostly Positive on Neurocrine Biosciences

    On October 4, Neurocrine Biosciences (NBIX) stock closed at $114.58, which is an ~3.79% decline from its October 3 close of $119.09.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Ionis Pharmaceuticals’ Revenue Growth Rate

    Ionis Pharmaceuticals (IONS) reported revenues of $262.0 million during the first half of 2018.

    By Mike Benson
  • uploads///Vertex
    Company & Industry Overviews

    How Vertex Pharmaceuticals Is Positioned Financially

    In the first half of this year, Vertex Pharmaceuticals’ (VRTX) revenue grew ~40% YoY (year-over-year) to $1.4 billion from $994.6 million.

    By Daniel Collins
  • uploads///Vertex
    Company & Industry Overviews

    Vertex Pharmaceuticals Strengthens in the Cystic Fibrosis Space

    Vertex Pharmaceuticals (VRTX) develops medicines for life-threatening diseases and is presently focused on developing drugs for cystic fibrosis and sickle-cell disease, partnering with CRISPR Therapeutics (CRSP) for the latter.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Estimates and Recommendations for Bluebird Bio on September 6

    Wall Street analysts estimate that Bluebird Bio (BLUE) will report a 14.6% growth in revenues to ~$40.6 million in 2018 compared to $35.4 million in 2017.

    By Mike Benson
  • uploads///hospital _
    Company & Industry Overviews

    Bluebird Bio’s Valuation on September 6

    Bluebird Bio (BLUE) reported a net loss of $2.91 per share on revenues of $7.8 million in Q2 2018, a 53% decline year-over-year.

    By Mike Benson
  • uploads///BMRN
    Company & Industry Overviews

    How BioMarin Pharmaceutical Is Positioned Financially in August

    In the second quarter, BioMarin Pharmaceutical (BMRN) reported revenues of $372.8 million compared to $317.4 million in Q2 2017.

    By Daniel Collins
  • uploads///addiction _
    Company & Industry Overviews

    How Analysts View BioMarin Pharmaceutical in August

    On August 30, 2018, BioMarin Pharmaceutical (BMRN) stock closed at $99.26 which is 7% below its 52-week high of $106.20 on August 2.

    By Daniel Collins
  • Company & Industry Overviews

    An Overview of Roche’s Immunology Drugs Pulmozyme and CellCept

    Roche’s CellCept generated revenues of 333.0 million Swiss francs in H1 2018 compared to 346.0 million Swiss francs in H1 2017.

    By Daniel Collins
  • uploads///laboratory _
    Company & Industry Overviews

    A Look at Incyte’s Valuation on August 22

    On August 22, Incyte was trading at a forward price-to-earnings multiple of 38.1x compared to the industry average of ~13.9x.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Why Vertex Is Expected to Report Robust EPS Growth in 2018

    Wall Street analysts have projected Vertex Pharmaceuticals’ fiscal 2018 adjusted diluted EPS to be around $3.8, which would be a YoY rise of approximately 93.1%.

    By Margaret Patrick
  • uploads///thermometer _
    Company & Industry Overviews

    Analyst Recommendations for Exelixis in August

    In the second quarter, Exelixis’s (EXEL) cabozantinib franchise generated revenues of $145.8 million, a 66% YoY growth.

    By Daniel Collins
  • uploads///Chart
    Earnings Report

    Analysts Are Bullish on Sarepta Therapeutics

    Sarepta Therapeutics (SRPT) reported revenues of $64.6 million and a net loss of $0.55 per share in Q1 2018.

    By Mike Benson
  • uploads///addiction _
    Earnings Report

    How Does BioMarin Pharmaceutical Look ahead of Its Q2 Earnings?

    BioMarin Pharmaceutical (BMRN) plans to release its Q2 2018 results on August 2. In Q1 2018, BMRN reported net revenues of $373.4 million.

    By Daniel Collins
  • uploads///VRTX
    Earnings Report

    Why Most Analysts Are Bullish on Vertex Pharmaceuticals

    Vertex Pharmaceuticals (VRTX) is expected to incur selling, general, and administrative expenses of $117.10 million in Q2 2018 as compared with $92.91 million in Q2 2017.

    By Kenneth Smith
  • uploads///pill _
    Earnings Report

    Will Vertex Pharmaceuticals Meet Analysts’ Q2 Expectations?

    Analysts expect Vertex Pharmaceuticals’ revenues to increase by 31.65% from $516.91 million in Q2 2017 to $680.53 million in Q2 2018.

    By Kenneth Smith
  • uploads///human skeleton _
    Earnings Report

    How Exelixis Is Positioned ahead of Its Q2 2018 Earnings Release

    Exelixis (EXEL) is scheduled to report its second-quarter earnings results on August 1.

    By Daniel Collins
  • uploads///cells __
    Company & Industry Overviews

    What’s behind Gemphire Therapeutics’ Stock Price Rise

    On July 6, Gemphire Therapeutics (GEMP) stock closed at $8.09, ~70% higher than its 52-week low of $4.75 on May 7.

    By Daniel Collins
  • uploads///syringe _
    Company & Industry Overviews

    Incyte’s Valuations on July 6

    Incyte (INCY) posted revenues of $382.3 million in Q1 2018, a marginal decrease in YoY revenues compared to $384.1 million in Q1 2017.

    By Mike Benson
  • uploads///dna _
    Company & Industry Overviews

    How Ionis Pharmaceuticals’ Valuation Compares

    Ionis Pharmaceuticals (IONS), a therapeutics development leader, commercializes products in collaboration with other pharmaceutical companies.

    By Mike Benson
  • uploads///sym
    Company & Industry Overviews

    Could Symdeko Be Vertex Pharmaceuticals’ Long-Term Growth Driver?

    In June, Health Canada approved Vertex Pharmaceuticals’ Symdeko for the treatment of the underlying cause of cystic fibrosis in individuals over 12 years old.

    By Daniel Collins
  • uploads///headache pain pills medication
    Company & Industry Overviews

    Solid Biosciences’ Stock Price Rose 46.6% on June 19

    On June 19, 2018, Solid Biosciences’ (SLDB) stock price rose ~46.6% to $43.00. On June 19, the stock price hit a 52-week high of $54.84.

    By Daniel Collins
  • uploads///molecule
    Company & Industry Overviews

    CRISPR, Intellia, and Caribou Receive a US Genome-Editing Patent

    On June 19, the co-owners of intellectual property associated with CRISPR-Cas9 genome editing technology were granted a US patent.

    By Daniel Collins
  • uploads///dna _
    Company & Industry Overviews

    A Look at Incyte’s Valuation as of May 25

    Incyte reported EPS of -$0.19 on revenue of $382.3 million in Q1 2018 compared to revenue of $384.1 million in Q1 2017.

    By Mike Benson
  • uploads///MEI
    Company & Industry Overviews

    What Led to MEI Pharma Stock’s 55% Rise Last Week?

    MEI Pharma (MEIP) saw a 55% rise in its stock price between May 11 and May 18.

    By Daniel Collins
  • uploads///cells _
    Company & Industry Overviews

    CRISPR Stock Has Seen Soild Growth in the Last 12 Months

    CRISPR Therapeutics has risen 24% between May 11 and May 17.

    By Daniel Collins
  • uploads///FeI
    Earnings Report

    How Did Jazz Pharmaceuticals Perform in 1Q18?

    In 1Q18, Jazz Pharmaceuticals (JAZZ) generated revenue of $444.6 million compared to $376.1 million in 1Q17.

    By Daniel Collins
  • uploads///exe
    Earnings Report

    How Did Exelixis Perform in 1Q18?

    In 1Q18, Exelixis (EXEL) generated revenues of $212.3 million, compared to $80.89 million in 1Q17. In 1Q18, Exelixis witnessed ~77% growth on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Orkambi
    Earnings Report

    How Vertex Pharmaceuticals’ Drugs Performed in 1Q18

    In 1Q18, Vertex Pharmaceuticals’ (VRTX) Orkambi revenue rose ~20% YoY (year-over-year) to $354 million from $295 million.

    By Daniel Collins
  • uploads///Analysts
    Company & Industry Overviews

    Analysts’ Recommendations for BioMarin Pharmaceutical

    In March 2018, the EMA (European Medicines Agency) accepted BioMarin Pharmaceutical’s (BMRN) marketing authorization application for pegvaliase.

    By Daniel Collins
  • uploads///daniel frank  unsplash
    Company & Industry Overviews

    Why Regeneron Pharmaceuticals’ Stock Price Fell

    Of the 27 analysts tracking Regeneron Pharmaceuticals (REGN) in March, five recommended a “strong buy” and six analysts recommended a “buy.”

    By Daniel Collins
  • uploads///FD
    Company & Industry Overviews

    Alexion Pharmaceuticals in 4Q17 and Fiscal 2017

    In 4Q17, Alexion Pharmaceuticals (ALXN) generated revenues of $910 million, which reflected ~10% growth on a YoY (year-over-year) basis.

    By Daniel Collins
  • uploads///rare diseases
    Company & Industry Overviews

    Inside Pfizer’s Rare Disease Segment Performance in 2017

    In 4Q17, Pfizer’s BeneFix reported revenues of $150 million, which represents a ~11% decline YoY and a ~1% decline quarter-over-quarter.

    By Daniel Collins
  • uploads///Kalydeco
    Company & Industry Overviews

    How Did Kalydeco Perform in 4Q17 and 2017?

    In 4Q17, Vertex Pharmaceuticals’ (VRTX) Kalydeco generated revenues of $256 million, a ~45% increase on a year-over-year (or YoY) basis and 20% growth on a quarter-over-quarter (or QoQ) basis.

    By Daniel Collins
  • uploads///Analysts ratings
    Company & Industry Overviews

    Gilead Sciences on the Street in January: Analyst Recommendations

    In December 2017, Gilead Sciences (GILD) and its subsidiary specialized in cell therapy, Kite, entered into an agreement with Cell Design Labs.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Vertex Pharmaceuticals to Target 90% of Cystic Fibrosis Patients

    Vertex Pharmaceuticals (VRTX) is currently involved in evaluating four triple combination regimens comprised of tezacaftor, ivacaftor, and one of the next-generation correctors.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Vertex Pharmaceuticals Has Robust Late-Stage Research Pipeline

    On January 10, 2018, Vertex Pharmaceuticals announced that Orkambi has secured regulatory approval from the European Commission to treat CF patients ages six to 11 years.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Analyst Recommendations for Vertex Pharmaceuticals in January

    Of the 27 analysts covering Vertex Pharmaceuticals in January 2018, ten have recommended a “strong buy,” while 13 have recommended a “buy.”

    By Margaret Patrick
  • uploads///Bioverativ
    Company & Industry Overviews

    Analysts’ Recommendations for Bioverativ in January 2018

    Fourteen analysts were tracking Bioverativ in January 2018. Four analysts recommended “strong buys,” while two recommended “buys” on the stock.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    A Look at Ionis’s 3Q17 Revenue Stream

    Ionis Pharmaceuticals (IONS) reported a 9% rise in its revenue to $120.9 million in 3Q17 compared to $110.9 million in 3Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How’s Incyte’s Valuation in January 2018?

    Analysts expect Incyte Corporation’s revenue to rise ~26.7% to $413.8 million in 4Q17 compared to $326.5 million in 4Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Analysts’ Recommendations for Eli Lilly in December 2017

    Eli Lilly (LLY) stock has risen 16.1% over the last 12 months and 15.7% in 2017 year-to-date. Analysts are estimating the stock could fall 8.3% over the next 12 months.

    By Mike Benson
  • uploads///Analysts Ratings
    Company & Industry Overviews

    Analyst Recommendations for Alexion in December 2017

    Twenty-one analysts are tracking Alexion Pharmaceuticals in December 2017. Six of them are recommending a “strong buy,” while 12 are recommending a “buy.”

    By Daniel Collins
  • uploads///Analysts Ratings
    Company & Industry Overviews

    Analysts’ Recommendations for Regeneron

    Dupilumab could be long-term growth driver In October 2017, Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that their Phase 3 dupilumab study had met its primary and secondary endpoints. The study was conducted to evaluate the safety and efficacy of dupilumab for the treatment of individuals with severe steroid-dependent asthma. In the study, at 24 weeks, when […]

    By Daniel Collins
  • uploads///Analysts rating
    Earnings Report

    Analyst Recommendations for Vertex Pharmaceuticals in October

    After 3Q17, Vertex Pharmaceuticals (VRTX) increased its guidance for cystic fibrosis product revenues, from $1.87 billion–$2.1 billion to $2.10 billion–$2.15 billion.

    By Daniel Collins
  • uploads///Soliris
    Company & Industry Overviews

    Gauging Alexion’s 2018 Growth with Soliris

    In 2Q17, Alexion Pharmaceuticals’ (ALXN) Soliris generated revenues of ~$814 million, which represented a ~16% YoY rise and a ~4% QoQ rise.

    By Daniel Collins
  • uploads///graph_
    Company & Industry Overviews

    Analysts’ Recommendations for Mylan in September 2017

    In 2Q17, Mylan reported revenues close to $3.0 billion, which is a YoY rise of around 16.0%, mainly driven by increased sales in Europe and the Rest of World markets.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Analysts’ Recommendations for Regeneron in September 2017

    Of the 26 analysts covering Regeneron Pharmaceuticals in September 2017, seven rated the stock a “strong buy,” six rated it as a “buy,” and 12 rated it as a “hold.” One analyst rated the company as a “strong sell.”

    By Margaret Patrick
  • uploads///Defitelio
    Company & Industry Overviews

    How Is Jazz’s Defitelio Positioned after 2Q17?

    In 2Q17, Jazz Pharmaceuticals’ (JAZZ) Defitelio generated revenues of ~$30 million, which represents a ~10% fall YoY and a ~17% fall QoQ.

    By Daniel Collins
  • uploads///Analysts Ratings
    Company & Industry Overviews

    Behind Bioverativ’s Analyst Recommendations This September

    Of the 12 analysts tracking Bioverativ (BIVV), three recommend a “strong buy” for the stock, while one recommends a “buy,” and seven recommend a “hold.”

    By Daniel Collins
  • uploads///Orkambi Kalydeco
    Company & Industry Overviews

    How Are Orkambi and Kalydeco Positioned after 2Q17?

    In 2Q17, Vertex Pharmaceuticals’ (VRTX) Orkambi generated revenues of around $324 million, which reflected a whopping ~32% growth on a year-over-year (or YoY) basis and ~10% growth on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///VX
    Company & Industry Overviews

    Vertex Presented Successful Results for Cystic Fibrosis Treatment

    Vertex Pharmaceuticals’ peers that are actively conducting research and development for CF drugs include Pfizer (PFE), PTC Therapeutics (PTCT), Proteostasis Therapeutics (PTI), Novartis, and Roche.

    By Daniel Collins
  • uploads///VX
    Company & Industry Overviews

    Vertex Saw Successful Results from VX-440 Phase 2 Study

    The positive data from the clinical trials will likely help Vertex Pharmaceuticals commercialize the drug.

    By Daniel Collins
  • uploads///Rare disease
    Company & Industry Overviews

    How Pfizer’s Rare Disease Franchise Stands after 2Q17

    In 1H17, BeneFix generated revenues of ~$302 million, which reflected an ~18% decline on a YoY basis.

    By Daniel Collins
  • uploads///Analyst recommendations
    Company & Industry Overviews

    Analyst Recommendations for Regeneron Pharmaceuticals in August

    Twenty-five analysts were analyzing Regeneron Pharmaceuticals in August 2017. Seven of them recommended a “strong buy,” and five recommended a “buy.”

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    New Patients and Alexion Pharmaceuticals’ Metabolic Franchise

    Alexion Pharmaceuticals (ALXN) has reiterated its 2017 revenue guidance of $375.0 million–$400.0 million for its metabolic franchise.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Alexion Pharmaceuticals Expects Robust Revenue for Soliris

    Alexion Pharmaceuticals (ALXN) raised its 2017 revenue projections for Soliris from $3.025 billion–$3.1 billion to $3.075 billion–$3.125 billion.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Alexion Pharmaceuticals Raised 2017 Earnings Guidance

    Alexion Pharmaceuticals (ALXN) raised its 2017 non-GAAP guidance from the previously estimated $5.10–$5.30 to $5.40–$5.55.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Alprolix and Eloctate Increasingly Used for Prophylaxis in 2017

    Since demand from the target population for prophylaxis is rising rapidly, Bioverativ’s Alprolix and Eloctate are expected to see solid demand trends in 2017.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Bioverativ Expected to Report Healthy Profit Margins in 2017

    Bioverativ (BIVV) expects its 2017 GAAP and non-GAAP operating margins to fall 38.0%–42.0% and 43.0%–47.0%, respectively.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Bioverativ Expected to Report Robust Revenue Growth in 2017

    In 1Q17, Bioverativ reported revenues close to $259.0 million, driven by its focus on a commercial strategy for its hemophilia products and optimal cost management.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Bioverativ–True North Therapeutics: Stronger Research Pipeline

    The acquisition of True North Therapeutics has paved the way for Bioverativ’s (BIVV) entry into cold agglutinin disease (or CAD).

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Vertex Pharmaceuticals’ Focus on Innovative Combination Regimens

    On March 28, 2017, Vertex Pharmaceutical (VRTX) released data from a phase 3 trial, EVOLVE.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Vertex Pharmaceuticals: Robust Growth Trends for Kalydeco in 2017

    In 1Q17, Vertex Pharmaceuticals’ (VRTX) Kalydeco reported revenues close to $186 million, of which $102 million came from the US market.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Vertex Pharmaceuticals Cystic Fibrosis Market Could Expand

    Vertex Pharmaceuticals’ (VRTX) drugs, Orkambi (lumacaftor/ivacaftor) and Kalydeco (ivacaftor), are capable of treating around 30,000 cystic fibrosis (or CF) patients.

    By Margaret Patrick
  • uploads///Chart  BIIB
    Miscellaneous

    What Drove Biogen Stock in 2Q17?

    Biogen (BIIB) stock has risen ~0.40% in 2Q17 and ~4.1% year-to-date as of July 7, 2017.

    By Mike Benson
  • uploads///BioMarin performance projections
    Company & Industry Overviews

    What to Expect from BioMarin Pharmaceuticals in 2017

    In 2016, BioMarin Pharmaceuticals (BMRN) reported revenues of around $1.1 billion, a ~25% increase year-over-year (or YoY).

    By Daniel Collins
  • uploads///pipeline
    Company & Industry Overviews

    Inside Vertex Pharmaceuticals’ Clinical Pipeline

    In March 2017, Vertex Pharmaceuticals (VRTX) announced promising results from two phase-3 clinical trials, Evolve and Expand.

    By Daniel Collins
  • uploads///Vertex Pharma Revenues
    Company & Industry Overviews

    Inside Vertex Pharmaceuticals’ Revenue Trend

    In 2016, Vertex Pharmaceuticals (VRTX) reported revenues of around ~$1.7 billion, which reflected a whopping 65% YoY (year-over-year) growth.

    By Daniel Collins
  • uploads///Analysts Ratings
    Company & Industry Overviews

    What Analysts Recommend for Celgene in 2017

    Celgene (CELG) has a focused and robust clinical pipeline that may help it launch new drugs in the future.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    How Incyte’s Valuation Has Changed since 1Q17 Results

    Incyte reported revenues of $384.1 million in 1Q17 as compared to $263.5 million in 1Q16.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    ALXN1210 Is Expected to Boost Alexion Pharmaceuticals’ Revenue

    Alexion Pharmaceuticals has planned five clinical trials in 2017 to test the potential of investigational next-generation C5 antibody, ALXN1210, as a treatment option for complement-mediated diseases.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Alexion Pharmaceuticals Projects Robust 2017 Revenue Performance

    Alexion Pharmaceuticals (ALXN) expects to report revenue in the range of $3.4 billion–$3.5 billion in 2017.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Biogen’s Targeted Marketing Strategy for Spinraza in 1Q17

    To promote the use of Spinraza for SMA, Biogen (BIIB) has been actively educating and creating awareness for the drug among physician and patient communities.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Biogen Has Developed a Robust Access Strategy for Spinraza

    In 1Q17, Biogen’s (BIIB) Spinraza earned revenues of $47.0 million, of which $46.0 million were from the US market.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Biogen’s Spinraza Witnessed Robust Patient Demand in 1Q17

    Spinraza, Biogen’s (BIIB) SMA (spinal muscular atrophy) therapy, was approved by the FDA (U.S. Food and Drug Administration) on December 23, 2016.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Will Regeneron’s Revenue Surpass Analysts’ Estimates in 1Q17?

    In 2017, Regeneron expects its eye drug, Eylea, to witness single-digit revenue growth on a year-over-year basis. Eylea has continued to be the company’s major revenue driver in the year.

    By Margaret Patrick
  • uploads///Graph
    Miscellaneous

    Failed Healthcare Bill Will Impact the Pharmaceutical Industry

    Due to the failure of the new healthcare bill, major pharmaceutical companies witnessed a fall in their share prices from March 23, 2017, to March 27, 2017.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    Ionis’s Subsidiary Akcea Therapeutics and Volanesorsen

    Ionis Pharmaceuticals (IONS) formed Akcea Therapeutics, a wholly owned subsidiary, to develop and commercialize volanesorsen.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    A Look at Ionis Pharmaceuticals’ Spinraza

    Ionis Pharmaceuticals’ (IONS) Spinraza (nusinersen) is designed for the treatment of spinal muscular atrophy, a type of severe motor-neuron disease.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Alnylam Pharmaceuticals’s Therapies to Treat hATTR Amyloidosis

    The European Medicines Agency (or EMA) has approved tafamidis for stage 1 hATTR amyloidosis.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    How Do Analysts View Alnylam Pharmaceuticals in 2017?

    Of the 15 analysts covering Alnylam Pharmaceuticals (ALNY) in February 2017, two rated the company as a “strong buy,” six rated it as a “buy,” and seven rated ALNY as a “hold.”

    By Margaret Patrick
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.